Abstract
We report a case of skin rashes that occurred in a 20-year-old South Indian female of Pittakaphala prakruthi (constitution) after beginning therapy with Aragwadadi kashaya (poly-herbal formulation) for the treatment of recurrent incidence of abscess. Rash disappeared after stopping the suspected drug and treatment with Vibhitaki kashaya (decotion of Terminalia bellarica) and Shataduta gruta (washed ghee). Possible and Probable (Score 6) were the causality according to WHO-UMC and Naranjo’s ADR Probability Scale and grouped under type-B reaction. To our knowledge, this is the first case of skin rashes induced by Aragwadadi kashaya and syp Talekt. This report highlights the need of implementation of Pharmacovigilance centre in hospital level and additional research in the field of skin toxicity of Aragwadadi kashaya and syp Talekt.

Keywords: Skin rashes; Aragwadadi kashaya; Talekt; Abscess; Ayurveda

Introduction
Rashes are most common cutaneous ADRs to any type of drugs and appear within first week of the drug therapy [1]. Overall incidence of allergic drug reactions is variously reported as being between 2 to 25% [2,3]. Common causes of skin rashes are infective, drug, sensitive skin, and some of known cutaneous eruption by Penicillin, Phenytin, Sulphonamide, Sulphonylurea, Thiazide, antituberculous drugs, antimalarial, penicillamine, ampicillin, amoxicillin etc [4]. “Ayurveda” is an ancient system of healthcare that is native to India. There are references in Ayurvedic literature on way in which drug induced consequences. Such as, manifestation of skin diseases on external administration of juice of Ballathaka (Semecarpus anacardium) [5], by suppressing urge of Charddi (vomiting) [6], Vamana mithyayoga (inadequate administration of emesis) [7], Dashanga lepa (poly herbal formulation) induced skin rashes [8] and thyroiditis followed by ginger consumption [9].

Recurrent mucocutaneous infection is a common clinical problem. The most common causes are immune deficiency, chronic skin disease, Diabetes Mellitus (DM) and inflammatory bowel disease (IBD) [10].

Aragwadadi Kashaya(ARK) is well known herbexcious decoction of Ayurveda used to treat various skin ailments. It contains Cassia fistula Linn, Holarrhenaantidiyserterica Wall, Stereosepmumnuveolens DC, SwertiachirataBuch.Ham, Azadirachtaidendrica A.juss, Tinosporacordifolia (Willd.Miers, Marsdeniatenacissima Wight and Arn, SolanumxanthocarpumSchrad&Wendl, Cissampelospareira Linn, Andrographispaniculata Wall.ex Nees, Barlieriaprinotis Linn, TrichosanzhesdioicaRoxb, Pongamiapinnata (Linn) Merr, Holopteleaintegifolia Planch, Alstoniascholaris R.B, Plumbagozeylanica Linn, ElettariacardamomumMaton, RandiadiometorumLamkZizyphusjujuba Mill as ingredients and it is therapeutically indicated in Emesis, Morbidity due to Poisonous substance, Disorders due to vitiation of Kaphadosha, Urinary disorders, Non-healing ulcer and skin diseases [11]. Syp Talekt was another patent formulation) for the treatment of reccurent incidence of abscess. Rash disappeared after stopping the suspected drug and treatment with Vibhitaki kashaya (decotion of Terminalia bellarica) and Shataduta gruta (washed ghee). Possible and Probable (Score 6) were the causality according to WHO-UMC and Naranjo’s ADR Probability Scale and grouped under type-B reaction. To our knowledge, this is the first case of skin rashes induced by Aragwadadi kashaya and syp Talekt. This report highlights the need of implementation of Pharmacovigilance centre in hospital level and additional research in the field of skin toxicity of Aragwadadi kashaya and syp Talekt.

These formulations are found to be safe and dermatological manifestations are extremely rare. This article discusses a case of skin rash in apatient on oral administration of ARK and Syp Talekt.

Case Report
A 20-year-old South Indian female of Pittakaphala prakruthi (constitution), who had a resident of Belgaum, Karnataka since birth, was consulted for abscess in right thigh that had developed 3-months back together with fever and myalgia. On administration of ARK3tsf with water and syp Talekt 3tsf with water, she has presented widespread skin rashes involving the abdomen, thighs, and upper arms (Figures 1 and 2). No mucosal involvement was noted. The remainder of the physical examination was normal with no signs of conjunctivitis.

Her history includes regular incidence of abscess once in 6 to 9 months. A month back she was on Serratipeptidase with Diclofenac sodium (15:200 mg) with dose of 1tb b.i.dfor 7-days and patient was not known for allergy to any food, drugs or chemical preservative. Previous day of the event patient was on ARK 3 tsf with water before food thrice daily. On the next day along with previous drug syp Talekt was administered with dose of 3tsf with water before food in thrice daily.

After 3rdose of above medication when she woke from bed on the following dayshe experienced itching, redness with rashes. Subsequently syp-talekt was discontinued following worsening of event
administration respectively and severity was moderate. Dermatological reaction to ARK was not known, infact the present formulation is known for its vast therapeutic applications on skin disorders [10] hence, the present event cause is difficult to trace, but it can be attributed to Parabine (chemical preservative).

Parabine is a well known preservative used in many formulation it has known to cause skin irritation and contact dermatitis in selective paraben allergy individuals [12,13] hence, we believe present drug event could be hypersensitivity to the preservative even though patient history doesn’t include known allergy to preservatives.

Learning points

This may be the good example for unpredictable or idiosyncratic reaction because it is very hard to predict cause and effect relation in modern pharmacology or Ayurvedic pharmacologyas in Dashanga lepa induced skin rashes [8] so it may be grouped under type-B type of adverse drug reaction.

Such unpredictable adverse reactions are not necessarily due to errors or negligence. It is difficult to predict host susceptibility to such response and thus it becomes very important to document, evaluate and report such reactions so that it recurrence can be prevented in future.

The detection of unknown and unexpected relationship between drug exposure and adverse events is one of the major challenges of pharmacovigilance. It is likely for an unexpected adverse reaction to go unnoticed until a very substantial number of patients have been adversely affected. Early detection of unknown and unexpected adverse reactions depends upon proper identification of signals and voluntary reporting system. Identifying and reporting such events plays an important role in preventing its recurrence.

Developing a practice of identifying ADR and its reporting will play an important role in successful implementation of National pharmacovigilance program for Ayurveda Siddha and Unani (ASU) drugs.

This case has been reported to National pharmacovigilance centre for ASU drugs, Jamanagar, India on 08.01.2011.

References

